Merck (MRK) announced that the National Medical Products Administration of China approved Gardasil Vaccine for use in males 9-26 years of age to help prevent certain HPV-related cancers and diseases. The approval makes Gardasil the first HPV vaccine approved for use in males in China. Gardasil is now indicated in China to prevent anal cancers caused by HPV Types 16 and 18, genital warts caused by HPV Types 6 and 11, and the following precancerous or dysplastic lesions caused by HPV Types 6, 11, 16, and 18: grade 1, grade 2, and grade 3 anal intraepithelial neoplasia
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Merck price target lowered to $120 from $125 at UBS
- Merck downgraded to Hold from Buy at Truist
- Wuxi Biologics upgraded to Overweight from Neutral at JPMorgan
- Paychex to acquire Paycor HCM, Getty and Shutterstock to merge: Morning Buzz
- Wuxi Biologics to sell Irish vaccine facility to Merck for $500M, Reuters says